BidaskClub upgraded shares of NantHealth (NASDAQ:NH) from a sell rating to a hold rating in a research note released on Tuesday morning.
Several other research analysts have also recently issued reports on NH. Zacks Investment Research raised shares of NantHealth from a hold rating to a buy rating and set a $4.50 target price for the company in a report on Thursday, October 12th. Jefferies Group reissued a buy rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Finally, Canaccord Genuity reduced their target price on shares of NantHealth from $6.00 to $5.00 and set a buy rating for the company in a report on Friday, November 17th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $8.05.
NantHealth (NASDAQ NH) traded up $0.10 during midday trading on Tuesday, hitting $3.85. 115,286 shares of the company’s stock were exchanged, compared to its average volume of 208,431. The stock has a market capitalization of $406.24 and a PE ratio of -2.64. NantHealth has a fifty-two week low of $2.60 and a fifty-two week high of $9.86. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93.
NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. The business had revenue of $21.76 million during the quarter, compared to analysts’ expectations of $29.42 million. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) earnings per share. sell-side analysts forecast that NantHealth will post -1.35 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NH. Alliancebernstein L.P. purchased a new position in NantHealth in the second quarter valued at $102,000. GSA Capital Partners LLP purchased a new position in NantHealth in the second quarter valued at $121,000. Teachers Advisors LLC increased its holdings in NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares in the last quarter. California State Teachers Retirement System increased its holdings in NantHealth by 132.4% in the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after buying an additional 18,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in NantHealth in the third quarter valued at $180,000. 7.10% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/19/nanthealth-nh-lifted-to-hold-at-bidaskclub.html.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.